Cholesterol Drug Rejected By Britain's Health Service Because Of Cost And Lack Of Definitative Link To Actual Reduction Of Heart Attacks

UK Cost Watchdog Turns Down Amgen's New Cholesterol Drug by Ben Hirschler.  Reuters.  November 18, 2015.